{"id":11802,"date":"2023-11-09T23:13:00","date_gmt":"2023-11-09T15:13:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11802"},"modified":"2024-11-07T23:16:50","modified_gmt":"2024-11-07T15:16:50","slug":"sandoz-enters-euro-debt-market-with-2-1-billion-eurobond-issuance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11802","title":{"rendered":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance"},"content":{"rendered":"\n<p>Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of EUR 2.4 billion (USD 2.6 billion) and will be used for general corporate purposes following its spin-off from Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) last month.<\/p>\n\n\n\n<p><strong>Details of the Eurobond Issuance<\/strong><br>The newly issued bonds offer fixed interest rates of 3.97%, 4.22%, and 4.50%, with corresponding maturities of 3.5, 6.5, and 10 years. This strategic move not only strengthens Sandoz&#8217;s financial position but also reflects the company&#8217;s commitment to diversifying its funding sources and managing its debt profile efficiently.<\/p>\n\n\n\n<p><strong>Repayment of Bridge Loan and Corporate Purposes<\/strong><br>The funds raised through the Eurobond issuance will be instrumental in repaying the EUR 2.4 billion bridge loan that Sandoz incurred during its separation from Novartis. The remaining funds will be allocated to general corporate purposes, providing Sandoz with the financial flexibility to pursue its strategic initiatives and growth plans in the competitive generics and biosimilars industry.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[20,140,865,747,886],"class_list":["post-11802","post","type-post","status-publish","format-standard","hentry","category-company","tag-finance","tag-novartis","tag-nyse-nvs","tag-sandoz","tag-swx-sdz"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of EUR 2.4 billion (USD 2.6 billion) and will be used for general corporate purposes following its spin-off from Novartis (NYSE: NVS) last month.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11802\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11802\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-09T15:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-07T15:16:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance\",\"datePublished\":\"2023-11-09T15:13:00+00:00\",\"dateModified\":\"2024-11-07T15:16:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Novartis\",\"NYSE: NVS\",\"Sandoz\",\"SWX: SDZ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11802#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11802\",\"name\":\"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-09T15:13:00+00:00\",\"dateModified\":\"2024-11-07T15:16:50+00:00\",\"description\":\"Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of EUR 2.4 billion (USD 2.6 billion) and will be used for general corporate purposes following its spin-off from Novartis (NYSE: NVS) last month.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11802\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11802#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance - Insight, China&#039;s Pharmaceutical Industry","description":"Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of EUR 2.4 billion (USD 2.6 billion) and will be used for general corporate purposes following its spin-off from Novartis (NYSE: NVS) last month.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11802","og_locale":"en_US","og_type":"article","og_title":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11802","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-09T15:13:00+00:00","article_modified_time":"2024-11-07T15:16:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11802#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11802"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance","datePublished":"2023-11-09T15:13:00+00:00","dateModified":"2024-11-07T15:16:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11802"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Novartis","NYSE: NVS","Sandoz","SWX: SDZ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11802#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11802","url":"https:\/\/flcube.com\/?p=11802","name":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-09T15:13:00+00:00","dateModified":"2024-11-07T15:16:50+00:00","description":"Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of EUR 2.4 billion (USD 2.6 billion) and will be used for general corporate purposes following its spin-off from Novartis (NYSE: NVS) last month.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11802#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11802"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11802#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11802"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11802\/revisions"}],"predecessor-version":[{"id":11803,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11802\/revisions\/11803"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}